Phase 1Not yet recruitingAge-related condition

5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses (5FU/C for AKs)

Sponsor
Cedars-Sinai Medical Center (Academic or other)
Enrollment
96 planned
Conditions
Actinic Keratoses
Interventions
Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C)
Ages
adults, older adults
Registry
NCT07794059

Full record on ClinicalTrials.gov

From the registry

Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C) has become standard of care among dermatologists for the field treatment of diffuse actinic keratoses (AKs). Data suggest that the addition of calcipotriene elicits a sustained T cell memory allowing for both short and long-term AK clearance. Our objective is to evaluate the efficacy, as well as, document the timing, severity and duration of local cutaneous reactions to topical treatment with 5FU/C for the treatment of AKs.

Primary outcomes

  • To assess the clinical efficacy of 5FU/C to treat Actinic Keratoses

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered